ALBERT LABS INTL. CORP. (VB50) - Net Assets
Based on the latest financial reports, ALBERT LABS INTL. CORP. (VB50) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore VB50 cash flow metrics to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALBERT LABS INTL. CORP. - Net Assets Trend (2021–2022)
This chart illustrates how ALBERT LABS INTL. CORP.'s net assets have evolved over time, based on quarterly financial data. Also explore ALBERT LABS INTL. CORP. (VB50) total assets for the complete picture of this company's asset base.
Annual Net Assets for ALBERT LABS INTL. CORP. (2021–2022)
The table below shows the annual net assets of ALBERT LABS INTL. CORP. from 2021 to 2022. For live valuation and market cap data, see ALBERT LABS INTL. CORP. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €-365.32K ≈ $-427.09K |
+27.30% |
| 2021-12-31 | €-502.53K ≈ $-587.51K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ALBERT LABS INTL. CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 705881300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.01 Million | % |
| Total Equity | €-365.32K | 100.00% |
ALBERT LABS INTL. CORP. Competitors by Market Cap
The table below lists competitors of ALBERT LABS INTL. CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cyanconnode Holdings PLC
LSE:CYAN
|
$372.64K |
|
HODL SPAC EUROPE AB
F:NW1
|
$373.18K |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
$373.53K |
|
Manx Financial Group Plc
LSE:MFX
|
$373.99K |
|
James Cropper PLC
LSE:CRPR
|
$372.01K |
|
Tinybuild Inc
LSE:TBLD
|
$370.85K |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
$370.80K |
|
PT Sreeya Sewu Indonesia Tbk
JK:SIPD
|
$368.37K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALBERT LABS INTL. CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -502,526 to -365,317, a change of 137,209.
- Net loss of 7,058,813 reduced equity.
- New share issuances of 1,511,408 increased equity.
- Other factors increased equity by 5,684,614.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.06 Million | -1932.24% |
| Share Issuances | €1.51 Million | +413.73% |
| Other Changes | €5.68 Million | +1556.08% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares ALBERT LABS INTL. CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-0.01 | €0.01 | x |
| 2022-12-31 | €-0.01 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ALBERT LABS INTL. CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.83 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-7.02 Million |
Industry Comparison
This section compares ALBERT LABS INTL. CORP.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $223,512,703
- Average return on equity (ROE) among peers: -29.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALBERT LABS INTL. CORP. (VB50) | €- | 0.00% | N/A | $372.07K |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.